title: Dapsone drug resistance in the MDT era.
authors.forename: P W
authors.initials: PW
authors.lastname: Roche
authors.forename: K D
authors.initials: KD
authors.lastname: Neupane
authors.forename: S S
authors.initials: SS
authors.lastname: Failbus
authors.forename: C R
authors.initials: CR
authors.lastname: Butlin
mesh_terms: D002991:Clofazimine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D003622:Dapsone / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D006801:Humans; D007917:Leprostatic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D007918:Leprosy / Q000188:drug therapy* / Q000453:epidemiology; D009166:Mycobacterium leprae / Q000187:drug effects*; D009390:Nepal / Q000453:epidemiology; D015995:Prevalence; D012293:Rifampin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D007917:Leprostatic Agents; D003622:Dapsone; D002991:Clofazimine; D012293:Rifampin